Vitamin K and Hepatocellular Carcinoma Prognosis: A Systematic Review and Meta-Analysis

Eleven studies involving 688 subjects were analyzed to evaluate vitamin K as an adjunctive therapy for hepatocellular carcinoma. The meta-analysis found the combination improved progression-free survival and reduced recurrence risk, particularly for patients receiving transarterial chemoembolization. This systematic review was authored by Lang Guo and published on figshare in March 2026.

Use Cases

• Evaluating the efficacy of vitamin K on progression-free survival based on pooled hazard ratios from 11 studies
• Assessing recurrence risk reduction in hepatocellular carcinoma patients based on meta-analysis results
• Comparing treatment outcomes between surgery and TACE subgroups based on the described subgroup analysis
• Informing clinical trial design for vitamin K dosing and administration strategies based on the study's conclusions

Strengths

• Analysis is based on 11 studies with a total of 688 subjects, providing a quantitative synthesis.
• Methodological quality was assessed using standardized tools (Newcastle-Ottawa Scale, Cochrane RoB-2).
• Results include specific pooled hazard ratios and confidence intervals for overall survival, progression-free survival, and recurrence risk.

Limitations

• The dataset is a 543.4 KB DOCX file, which is a small document rather than a raw research dataset.
• Row count and column-level documentation are absent; the file contains the analysis report, not the underlying trial data.
• Data may reflect publication or selection bias inherent to the systematic review's inclusion criteria.

Provenance

Source

figshare, author Lang Guo

Collection Method

Systematic review and meta-analysis of randomized controlled trials and cohort studies from databases including PubMed and Embase.

Freshness

Last updated 2026-03-18 05:21:35